All News

Individuals with learning disabilities face a heightened risk of severe type 2 diabetes (T2D), leading to increased mortality despite better glycemic control.

New findings suggest high-dose influenza vaccines offer better protection against the flu and reduce cardiac complications in older adults.

Katherine Saunders, MD, weighs in on orforglipron’s potential to expand obesity treatment options, improve adherence with a simple oral regimen, and address barriers to care and access.

Pharmacies increasingly dispense buprenorphine, enhancing access to opioid addiction treatment while embracing AI and telepharmacy innovations for better care.

A single dose of an RSV vaccine significantly reduces hospitalization risk for older adults, offering protection for 2 seasons against severe infections.

GLP-1 medications like semaglutide and tirzepatide significantly lower heart failure hospitalization risks, expanding treatment options for obesity-related conditions.

Pharmaceutical companies must consider formulation, packaging, and labeling from the start to minimize errors and protect patients.

Azelastine, commonly used in nasal sprays to combat allergies, was found to reduce the incidence of SARS-CoV-2 among healthy controls in a phase 2 trial.

Zongertinib promises significant advancements in patient care.

Reduced-dose apixaban maintains efficacy with less bleeding for extended CAT prophylaxis, reinforcing NCCN’s preexisting guidance in intermediate to high-risk cancer patients.

Research reveals associations between body composition, fitness, and mental health in children, highlighting the impact of obesity on anxiety and depression.

New research reveals that women on beta-blockers post-heart attack face a 45% higher risk of serious health issues compared with men.

Women using depot medroxyprogesterone acetate face a significantly higher risk of meningioma, especially with long-term use or starting after age 31.

By targeting 2 chromatin complexes that jointly sustain ER‑driven transcription, this combination achieves superior suppression of tumor growth and gene expression.

David Eagle, MD, Chair of Legislative Affairs and Patient Advocacy, explains how CMS’s ban on community oncology practices mailing medications creates inequities with PBMs and adds burdens for vulnerable cancer patients.

Compared with rivaroxaban, abelacimab significantly lowered bleeding risk in patients with atrial fibrillation regardless of kidney function.

A new oral PCSK9 inhibitor, enlicitide, shows promise in significantly lowering LDL cholesterol, offering hope for hypercholesterolemia management and cardiovascular health.

A retrospective analysis found widespread lack of low-density lipoprotein cholesterol (LDL-C) goal attainment, posing risks for those at very high cardiovascular risk.

Moderate-to-severe TBI significantly increases the risk of malignant brain tumors, highlighting the need for long-term monitoring in survivors.

Abemaciclib significantly enhances overall survival in high-risk HR+, HER2- early breast cancer, establishing a new standard of care.

Subcutaneous bortezomib shows fewer adverse effects in multiple myeloma treatment compared with intravenous administration, enhancing patient outcomes.

This decision is believed to redefine how biological drugs will be developed, approved, and made affordable for patients.

Susan Cantrell, RPh, MHL, CAE, highlights the Equitable Community Access to Pharmacy Services (ECAPS) Act as the top federal priority to preserve pharmacists’ authority in testing, treatment, and immunization services.

Fast-melt tablets (FMT) in drug delivery enhanced patient adherence and therapeutic response.

The approval of 2 denosumab biosimilars, Bildyos and Bilprevda, enhances access to affordable bone health treatments for patients.

Vaccination is vital for adults with heart disease to prevent severe respiratory illnesses like RSV, influenza, and COVID-19, enhancing overall health outcomes.

Greater effectiveness was seen in children 1 year and older.

Rilzabrutinib gained FDA approval as the first BTK inhibitor for chronic immune thrombocytopenia, offering new hope for patients with persistent symptoms.